Intimation of outcome of Board meeting held on May 21, 2026.
AUROPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Aurobindo Pharma's Board approved audited financial results for Q4 and FY2026. Standalone profit after tax rose 38% to ₹24,148 million, while consolidated PAT grew marginally to ₹35,030 million. Total consolidated revenue from operations stood at ₹3,36,531 million. The company completed a ₹8,000 million share buyback in May 2026. Auditors Deloitte issued unmodified opinions. The Board also accepted resignation of secretarial auditors MRR & Associates and appointed RPR & Associates in their place, while reappointing Ernst & Young as internal auditors.
Strong standalone earnings growth with 38% PAT increase reflects operational strength. The completed buyback returns cash to shareholders. Pending acquisitions of Lannett Company and Khandelwal's formulations business signal expansion strategy.